Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu

  – The MINISTONE-2 study showed XOFLUZA, given as a new oral suspension, is a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years – – Approximately one in three children develop the flu every year and they are often contagious longer than adults – treating children may therefore help reduce symptoms and prevent the spread of the flu to the wider community – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jul. 3, 2019– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III MINISTONE-2 study met its primary endpoint, demonstrating that XOFLUZA™ (baloxavir marboxil) was well-tolerated in children with the flu. The study also showed that XOFLUZA is comparable to oseltamivir – a proven effective treatment for children with the flu – at reducing the duration of flu symptoms, including fever. The study assessed XOFLUZA versus ...

• Source: drugdu
• 1,367
• August 2, 2019